Clinical Medicine and Diagnostics

Clinical Medicine and Diagnostics is a peer-reviewed journal publishing papers of significance in all areas of medical sciences. Articles include original research papers, reviews and short research communications. Submissions of basic and clinical research are both considered.

Srinivasan Madhusudan

Editorial Board Member of Clinical Medicine and Diagnostics

Associate Professor, University of Nottingham, UK

Research Areas

Medical Oncology, Translational Cancer Research, Cancer Therapy, Cancer Biomarkers, Drug Discovery, Dna Repair

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Mohammed MZ, Vyjayanti VN, Laughton C, Dekker L, Fischer PM, Wilson DM, Abbotts R, Patel PM, Hickson ID, and Madhusudan S. Development and evaluation of human AP endonuclease (APE1) inhibitors in Melanoma and Glioma cell lines. British Journal of Cancer 2011 Feb 15;104(4):653-63
[2]  Zhang J, Stevens MFG., Hummersone M, Madhusudan S, Laughton CA., Bradshaw TD Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair. Oncology 2011;80(3-4):195-207.
[3]  Gossage L, Perry C, Abbotts R, and Madhusudan S. Base excision repair factors are promising prognostic and predictive markers in cancer. Current Molecular Pharmacology 2011. In Press
[4]  Murali-Ganesh R, Malhotra R, Perry C, Madhusudan S. Human apurinic/apyrimidinic endonuclease (APE1): An emerging anti-cancer biomarker. Recent patents on biomarkers 2011. In Press
[5]  Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo D N, Harris AL and Madhusudan S. Expression of key hypoxia sensing prolyl-hydroxylases PhD-1, 2 and 3 in pancreatico-biliary cancer. Histopathology. 2010, 56(7):908-20
[6]  Fareed KR, Al-Attar A, Soomro IN, S., Kaye PV, Lobo DN, Parsons SL and Madhusudan S. Tumour regression and ERCC1 nuclear protein expression predicts clinical outcome in patients with gastro-oesophageal cancer treated with neo-adjuvant chemotherapy. British Journal of Cancer 2010, 25;102(11):1600-7
[7]  Al-Attar A, Gossage L, Fareed KR, Shehata M, Abbotts R, Zaitoun A, Soomro I, Lobo DN, Parson SL, Chan S and Madhusudan S. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. British Journal of Cancer 2010, 102(4):704-9.
[8]  Abbotts R and Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treatment Reviews, 2010.36(5):425-35
[9]  Valle J, Wasan H, Palmer D, Cunningham D, Anthony A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Roughton M, Pereira S, Bridgewater J. Cisplatin and gemcitabine for advanced biliary tract cancer. New England Journal of Medicine, 2010, 362(14);1273–1281
[10]  Malhotra S, Wood J, Mansy T, Singh R, Zaitoun A, and Madhusudan S. Intrahepatic sarcomatoid cholangiocarcinoma. Journal of Oncology, 2010. In Press
[11]  Zhang J, Stevens MFG, Laughton CA, Madhusudan S, Bradshaw TD. Acquired resistance to Temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010;78:103-114..
[12]  Halliday V, Kierczuk G, Madhusudan S, Parsons SL, Wilcock A. Screening for malnutrition: Implications for upper gastrointestinal cancer services. Journal of Surgical Oncology, 2009. Oct 29. [Epub ahead of print]
[13]  Fareed KR, Ilyas M, Kaye P, Soomro I, Lobo DN, Parson SL, Welch NT and Madhusudan S. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum based neoadjuvant chemotherapy. Histopathology, 2009, 55: 399–406.
[14]  Aloysius M, Lobo DN, Rowlands BJ, Madhusudan S, Ilyas M, Zaitoun A. HER2/Neu overexpression is a rare event in peri-ampullary cancers: assessment using the HercepTest . Histopathology, 2009 Aug;55(2):236-7.
[15]  Fareed K.R., Kaye P., Somroo I.N., Ilyas M, Martin S., Parsons S.L., Madhusudan S. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009;58(1):127-43.
[16]  Gossage L, Madhusudan S. Cancer Pharmacogenomics:the role of DNA repair genetic polymorphisms in individualising cancer therapy. Molecular Diagnosis & Therapy. 2007;11(6):361-80
[17]  Gossage L, Madhusudan S. Current status of Excision Repair Cross Complementing Group 1 (ERCC1) in cancer. Cancer Treatment Review. 2007; 33(6):565-77.
[18]  Madhusudan S, Ganesan TS. Intraperitoneal gene therapy. Cancer Treatment and Research. 2007;134:515-24
[19]  Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors and cancer therapy. Recent Results in Cancer Research. 2007;172:25-44
[20]  Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. A study of Etanercept (ENBREL), a tumour necrosis factor-inhibitor in recurrent ovarian cancer. Journal of Clinical Oncology. 2005;23(25):5950–59.
[21]  Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, Talbot DC, Hammonds T, Freemont PA, Sternberg JEM, Dianov GL, Hickson ID.Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Research. 2005; 33(15):4711-24.
[22]  Madhusudan S and Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends in Molecular Medicine. 2005;11(11):503-11.
[23]  Madhusudan S and Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treatment Reviews. 2005;31(8):603-17.
[24]  Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL.A phase II study of etanercept (Enbrel), a tumor necrosis factor-inhibitor in patients with metastatic breast cancer. Clinical Cancer Research. 2004;10(19):6528-34.
[25]  Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DP, Harper P, Seckl M, Thomas H, Lemoine NR, Charnock M, Habib NA, Lechler R, Nicholls J, Pignatelli M, Ganesan TS . A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clinical Cancer Research. 2004;10(9):2986-96.
[26]  Madhusudan S, Deplanque G, Braybrooke JP, Cattell E, Taylor M, Price P, Tsaloumas MD, Moore N, Huson SM, Adams C, Frith P, Scigalla P, Harris AL. Antiangiogenic therapy for von Hippel-Lindau disease. Journal of the American Medical Association. 2004;291(8):943-4.
[27]  Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry. 2004;37(7):618-35.
[28]  Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S, Harris AL. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. British Journal of Cancer. 2003;89(8):1418-22.
[29]  Madhusudan S, Harris AL. Drug inhibition of angiogenesis. Current Opinion in Pharmacology. 2002;2(4):403-14.
[30]  Madhusudan S, Abinun M, Cant AJ, Tan K, Oakhill A, Steward CG. Malignant infantile osteopetrosis presenting with neonatal hypocalcaemia. Archives of Diseases in Childhood (Fetal Neonatal Edition). 2000;83(1):21-3.
[31]  Deplanque G, Madhusudan S, Jones PH, Wellmann S, Christodoulos K, Talbot DC, Ganesan TS, Blann A, Harris AL. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. British Journal of Cancer. 2004;91(9):1645-50.
[32]  Levitt NC, Propper DJ, Madhusudan S, Braybrooke JP, Echeta C, Slevin M, Davies SL, Flanagan E, Joel S, Hickson ID, Ganesan TS. A Phase I study to investigate the activity and toxicity of the combination of topotecan and infusional etoposide phosphate in relapsed or recurrent ovarian cancer. British Journal of Cancer. 2005;93(1):60-9.
[33]  Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, White L, Kan O, Naylor S, Carroll MW, Kingsman SM, Harris AL.Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clinical Cancer Research. 2005;11(4):1512-20.
[34]  Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL, Talbot DC.Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clinical Cancer Research. 2003;9(13):4682-88.
[35]  Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL.Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clinical Cancer Research. 2003;9(5):1648-55.
[36]  Perry C, Sultana R, Madhusudan S-Chapter on 'Personalised cancer medicine: DNA repair alternations are promising predictive biomarkers in cancer' in DNA repair in cancer therapy: Molecular Targets and Clinical Application (1st edition). Publisher: Elsevier 2011.
[37]  Abbotts R, Perry C, Sultana R and Madhusudan S-Chapter on 'Human Apurinic/Apyrimidinic Endonuclease Is a Novel Drug Target in Cancer' in DNA repair (1st edition). Publisher: InTech 2011
[38]  Madhusudan S, Patterson D and Harris AL-Chapter on 'Angiogenesis as a target for the treatment of cancer' in Treatment of Cancer (5th Edition) pages 251-268. Arnold 2008 (ISBN 139780340912218)
[39]  Price CGA, Madhusudan S-Chapter on 'Non-Hodgkins Lymphoma' in Treatment of Cancer (4th Edition) pages 977-995. Arnold 2002 (ISBN 034075964 X)
[40]  Madhusudan S and Wilson D (Editors)-'DNA Repair and Cancer: Bench to Clinic'. Publisher: Science publishers, Enfield, USA. 2012 (ISBN 978-1-57808-742-6)
[41]  Afzal Mir M, Madhusudan S, Freeman AE-'The Complete PLAB: Objective Structured Clinical Examinations (OSCEs)'. Publisher: Churchill Livingstone 2002 (ISBN 0443070504).